Form 4: ACM Research CEO David Wang Sells 56,250 Shares Under 10b5-1 Trading Plan

Sentiment:

SEC Form 4 Filing


ACM Research CEO David Wang sold 56,250 shares of Class A Common Stock at an average price of $19.08, according to a recent SEC filing.

Summary

  • David H. Wang, CEO of ACM Research, sold 56,250 shares of Class A Common Stock on November 22, 2024.
  • The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2024, and amended on August 13, 2024.
  • The shares were sold at a weighted average price of $19.08, with individual transaction prices ranging from $18.80 to $19.29.
  • Following the transaction, Mr. Wang directly owns 710,506 shares of Class A Common Stock.
  • Mr. Wang also has indirect ownership of shares through his wife, daughter, and family trusts, totaling 945,840 shares.

Sentiment

Score: 5

Explanation: The document reports a routine insider sale under a pre-arranged plan, which is neither particularly positive nor negative. It's a neutral event.

Risks

  • Sales by insiders can sometimes be perceived negatively by the market, potentially impacting the stock price.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and these transactions are closely monitored by investors and regulators. The use of a 10b5-1 trading plan is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

  • The sale of shares by a CEO is not unusual, especially when conducted under a pre-arranged 10b5-1 trading plan.
  • Other technology company executives often use similar plans to manage their personal finances and avoid potential conflicts of interest.
  • The volume of shares sold is relatively small compared to the total outstanding shares of ACM Research, suggesting it is unlikely to have a significant impact on the stock price.

Stakeholder Impact

  • The sale may have a minor impact on shareholder sentiment, but is unlikely to have a significant impact on the company's operations or financial health.
  • The sale is unlikely to impact employees, customers, suppliers, or creditors.

Key Dates

DateDescription
05/14/2024Date the Rule 10b5-1 trading plan was adopted.
08/13/2024Date the Rule 10b5-1 trading plan was amended.
11/22/2024Date of the stock sale transaction.
11/26/2024Date of the SEC filing.

Keywords

ACM Research, David Wang, insider trading, SEC Form 4, stock sale, Rule 10b5-1, executive, share transaction

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.